Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5

BackgroundHIV infection in Africa is associated with immune activation and a cytokine profile that stimulates CCR5 expression. We investigated whether this immune activation is environmentally driven; if a dominant expression of CCR5 could indeed be detected in African individuals; and if R5 HIV strains would be prevalent in this population. MethodsFreshly drawn peripheral blood mononuclear cells from HIV-uninfected African and Italian individuals living in rural Africa, from HIV-uninfected Africans and Italians living in Italy, and from HIV-infected African and Italian patients were analysed. Determinations of HIV coreceptor-specific mRNAs and immunophenotype analyses were performed in all samples. Virological analyses included virus isolation and characterization of plasma neutralizing activity. FindingsResults showed that: immune activation is detected both in Italian and African HIV-uninfected individuals living in Africa but not in African subjects living in Italy; CCR5-specific mRNA is augmented and the surface expression of CCR5 is increased in African compared with Italian residents (CXCR4-specific mRNA is comparable); R5-HIV strains are isolated prevalently from lymphocytes of African HIV-infected patients; and plasma neutralizing activity in HIV-infected African patients is mostly specific for R5 strains. ConclusionsImmune activation in African residents is environmentally driven and not genetically predetermined. This immune activation results in a skewing of the CCR5 : CXCR4 ratio which is associated with a prevalent isolation of R5 viruses. These data suggest that the selection of the predominant virus strain within the population could be influenced by an immunologically driven pattern of HIV co receptor expression.

[1]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[2]  C. Brennan,et al.  Serologic and phylogenetic characterization of HIV‐1 subtypes in Uganda , 1997, AIDS.

[3]  C. Mackay,et al.  Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes , 1998, The Journal of experimental medicine.

[4]  J. Albert,et al.  REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.

[5]  J. Albert,et al.  Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Mackay,et al.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Albert,et al.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.

[8]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[9]  T. Quinn,et al.  Seroconversion rate, mortality, and clinical manifestations associated with the receipt of a human immunodeficiency virus-infected blood transfusion in Kinshasa, Zaire. , 1991, Journal of Infectious Diseases.

[10]  B. Autran,et al.  A Th0/Th2-like function of CD4+CD7- T helper cells from normal donors and HIV-infected patients. , 1995, Journal of immunology.

[11]  R. Hayes,et al.  Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV‐infected adults in Abidjan, Côte d'Ivoire , 1997, AIDS.

[12]  Z. Bentwich,et al.  Immune activation is a dominant factor in the pathogenesis of African AIDS. , 1995, Immunology today.

[13]  C. Katlama,et al.  CD4+CD7-CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. , 1992, Blood.

[14]  T. Quinn,et al.  Human immunodeficiency virus infection among employees in an African hospital. , 1988, The New England journal of medicine.

[15]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[16]  P. Van de Perre.  The epidemiology of HIV infection and AIDS in Africa. , 1995, Trends in microbiology.

[17]  A. Trkola,et al.  Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.

[18]  J. Albert,et al.  Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.

[19]  N. Nagelkerke,et al.  Comparison of the declines in CD4 counts in HIV-1-seropositive female sex workers and women from the general population in Nairobi, Kenya. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[20]  H. Schuitemaker,et al.  Infectious Cellular Load in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and Susceptibility of Peripheral Blood Mononuclear Cells from Their Exposed Partners to Non-Syncytium-Inducing HIV-1 as Major Determinants for HIV-1 Transmission in Homosexual Couples , 1998, Journal of Virology.

[21]  M. Baggiolini,et al.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes , 1996, The Journal of experimental medicine.

[22]  M. Wilkes,et al.  Health News Reporting: Reply , 1997, Annals of Internal Medicine.

[23]  H. Schuitemaker,et al.  Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection , 1997, Annals of Internal Medicine.

[24]  M. Moroni,et al.  Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. , 1996, Blood.

[25]  Characterization,et al.  Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. , 1994, AIDS research and human retroviruses.

[26]  Z. Bentwich,et al.  Increased CCR5 expression with decreased beta chemokine secretion in Ethiopians: relevance to AIDS in Africa. , 1999, Journal of human virology.

[27]  Z. Bentwich,et al.  Pathogenesis of AIDS in Africa - Lessons from the Ethiopian immigrants in Israel , 1997 .

[28]  J. Hoxie,et al.  Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage , 1998, Journal of Virology.

[29]  M. Clerici,et al.  Immunological activation markers in the serum of African and European HIV‐seropositive and seronegative individuals , 1996, AIDS.

[30]  P. Ferrante,et al.  Immune activation in HIV‐infected African individuals , 1998 .

[31]  A. Grant,et al.  Natural history and spectrum of disease in adults with HIV/AIDS in Africa. , 1997, AIDS.

[32]  S. Zolla-Pazner,et al.  Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage , 1998, Journal of Virology.

[33]  T. F. Rinke de Wit,et al.  HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.

[34]  F. Brun-Vézinet,et al.  Genetic diversity and HIV detection by polymerase chain reaction , 1995, The Lancet.

[35]  J. Albert,et al.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection , 1994, Journal of clinical microbiology.

[36]  J. Andersson,et al.  Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. , 1998, The American journal of pathology.

[37]  A. Trkola,et al.  Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage , 1998, Journal of Virology.

[38]  R. Lal,et al.  Adaptation to promiscuous usage of CC and CXC‐chemokine coreceptors in vivo correlates with HIV‐1 disease progression , 1998, AIDS.

[39]  M. Bakari,et al.  Survival time of patients with acquired immune deficiency syndrome: experience with 274 patients in Dar-es-Salaam. , 1990, East African medical journal.